Autopsy report · NCT01123473

Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer

“company withdrew interest”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 3 years 9 months before it stopped.
• 29 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC

Sponsor type

University, hospital or other

Conditions

Adenocarcinoma of the Gastroesophageal Junction; Gastric Cancer

Interventions

capecitabine; cisplatin; epirubicin hydrochloride; fluorouracil; lapatinib ditosylate

Participants

29

Sites

4

Countries

Belgium, Germany, Portugal

Trials that died the same way

• SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
  “Supporting company withdrew interest” (93% match in meaning)
• The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU
  “Withdrawn due to no funding” (65% match in meaning)
• Lucentis for New Onset Neovascular Glaucoma
  “Company withdrew funding/sponsorship” (65% match in meaning)
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  “funding was withdrawn” (64% match in meaning)
• Awbat Versus Biobrane in Partial Thickness Burns
  “Company went out of business” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.